Kidney Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Cardiopulmonary Events: Study Finds Small but Real Risk After Partial Nephrectomy
ESMO 2021: Update From KEYNOTE-427 With Pembrolizumab Monotherapy for Kidney Cancer
Trends in Renal Cell Carcinoma in Pennsylvania Over the Past 27 Years
ESMO 2021: Patient-Reported Outcomes From KEYNOTE-564 With Adjuvant Pembrolizumab for Kidney Cancer
ESMO 2021: Can Modified Dosing Schedule of Ipilimumab Improve Tolerability in Renal Cell Carcinoma?
ESMO 2021: Temporary Treatment Cessation Versus Continuation in Advanced Kidney Cancer
ESMO 2021: 5-Year Outcomes With Nivolumab Plus Ipilimumab in Kidney Cancer
AUA 2021: Immunotherapy and Cytoreductive Nephrectomy in Metastatic Kidney Cancer
AUA 2021: Role of the Tumor Microenvironment and Response to Axitinib in Renal Cell Carcinoma
AUA 2021: KEYNOTE-564 Focuses on Adjuvant Immunotherapy for Renal Cell Carcinoma
Immune Checkpoint Inhibition in Metastatic Kidney Cancer: Racial Differences in Outcomes?
Reversible Aminotransferase Elevation in Patients Treated With Pembrolizumab/Axitinib for Kidney Cancer
Myasthenia Gravis: A Paraneoplastic Syndrome Linked to Renal Cell Carcinoma?
Renal Cell Carcinoma: Neoadjuvant Radiation Followed by Nephrectomy and Thrombectomy
Belzutifan Approved by FDA for von Hippel-Lindau Disease Associated With Kidney Cancer
Lenvatinib Plus Pembrolizumab Approved by FDA for Advanced Renal Cell Carcinoma
FDA Grants Priority Review to Pembrolizumab as Adjuvant Therapy After Nephrectomy
JAVELIN Renal 101 Trial: Second-Line Treatment With Axitinib Plus Avelumab in Kidney Cancer
MET-Driven Kidney Cancer: Combination of Durvalumab and Savolitinib Under Study
CheckMate 920: Nivolumab Plus Ipilimumab for Renal Cell Carcinoma With Brain Metastases
Can Nephrectomy Prior to Immunotherapy Improve Survival in Renal Cell Carcinoma?
Lenvatinib Plus Pembrolizumab in Renal Cell Carcinoma: Phase IB/II Trial Results
Nivolumab Alone and in Combination Therapy for Non–Clear Cell Kidney Cancer
Lenvatinib/Everolimus in Advanced Kidney Cancer: Outcomes in a Real-World Setting
Do Patient Demographics Influence Treatment Decisions in Kidney Cancer?
New Use for Older Antifungal Agent: Adjunct to Therapy for Kidney Cancer?
ASCO 2021: Telaglenastat Plus Cabozantinib in Advanced Renal Cell Carcinoma
ASCO 2021: mTOR- and VEGF-Targeted Agents in Metastatic Renal Cell Carcinoma
ASCO 2021: Does Immunotherapy Improve Outcomes in Aggressive Subtype of Kidney Cancer?
ASCO 2021: Impact of Lenvatinib-Based Therapy on Quality of Life in Renal Cell Carcinoma
ASCO 2021: Can Live Bacterial Product Enhance Response to Immunotherapy in Metastatic Renal Cell Cancer?
Updated AUA Guidelines Focus on Renal Masses and Localized Renal Cancer
ASCO 2021: 42-Month Follow-up of Pembrolizumab Plus Axitinib in Advanced Clear Cell Kidney Cancer
ASCO 2021: KEYNOTE-564 Evaluates Pembrolizumab as Adjuvant Therapy After Nephrectomy
After Radical Nephrectomy: Risk Factors Associated With Locoregional Recurrence
Advanced Kidney Cancer in Arizona: Are Hispanic and Native Americans at Increased Risk of Mortality?
Brain Metastasis 15 Years After Radical Nephrectomy for Renal Cell Carcinoma: Case Report
CRP Flare Response and Response to Nivolumab in Kidney Cancer
Stereotactic Body Radiotherapy for Metastatic Kidney Cancer: U.S. Temporal Trends
FDA Grants Priority Review to Pembrolizumab/Lenvatinib Combination for Kidney Cancer
Chemerin Overexpression in Clear Cell Kidney Cancer: Lipid Metabolism and Tumorigenesis
Is Plasma KIM-1 Linked to Recurrence Risk After Nephrectomy?
CheckMate 9ER: Cabozantinib Plus Nivolumab Versus Sunitinib in Kidney Cancer
Asymptomatic CNS Involvement From Advanced Renal Cell Carcinoma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.